{"filing":{"accession_number":"0001213900-26-091677","cik":"0001721484","ticker":"LGVN","company_name":"Longeveron Inc.","form":"8-K","filing_date":"2026-08-19","report_date":"2026-08-17","primary_document":"ea0302723-8k_longeveron.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1721484/000121390026091677/ea0302723-8k_longeveron.htm"},"events":[{"id":28515,"run_id":26087,"accession_number":"0001213900-26-091677","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Longeveron appointed Nirav S. Jhaveri as Chief Financial Officer, principal financial officer and principal accounting officer effective August 17, 2026. The filing discloses his extensive 25+ years of biopharma leadership experience, prior CFO roles at public biotech companies (Opus Genetics, Insilico Medicine, Journey Medical), and his compensation package including $400,000 base salary, 45% performance bonus target, and 300,000 RSUs vesting over three years. This is a material executive appointment to a principal officer role at a clinical-stage biotech company.","company_name":"Longeveron Inc.","ticker":"LGVN","filing_date":"2026-08-19","form":"8-K","submitted_at":null,"items":[{"id":30482,"accession_number":"0001213900-26-091677","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Longeveron appointed Nirav S. Jhaveri as Chief Financial Officer, principal financial officer and principal accounting officer effective August 17, 2026. The filing discloses his extensive 25+ years of biopharma leadership experience, prior CFO roles at public biotech companies (Opus Genetics, Insilico Medicine, Journey Medical), and his compensation package including $400,000 base salary, 45% performance bonus target, and 300,000 RSUs vesting over three years. This is a material executive appointment to a principal officer role at a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T20:14:41.695322+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":30482,"accession_number":"0001213900-26-091677","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Longeveron appointed Nirav S. Jhaveri as Chief Financial Officer, principal financial officer and principal accounting officer effective August 17, 2026. The filing discloses his extensive 25+ years of biopharma leadership experience, prior CFO roles at public biotech companies (Opus Genetics, Insilico Medicine, Journey Medical), and his compensation package including $400,000 base salary, 45% performance bonus target, and 300,000 RSUs vesting over three years. This is a material executive appointment to a principal officer role at a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-19T20:14:41.695322+00:00","company_name":"Longeveron Inc.","ticker":"LGVN","filing_date":"2026-08-19"}]}